Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Researchers at UHN's Krembil Research Institute have revealed that a protein – known as syntaxin – could hold the key for new therapies for a variety of neurological disorders.
The study was led by Krembil Senior Scientist
Dr. Shuzo Sugita and was recently published in
Syntaxin plays a key role in how neurons – specialized cells in the brain and nervous system – transmit information throughout the body. Neurons communicate with other cells at narrow gaps known as synapses, where neurotransmitters are released.
These neurotransmitters serve to "bridge the gap" between the cells by passing on the signal.
The release of neurotransmitters is key to the process known as synaptic transmission, which enables the flow of electrical information between the brain, spinal cord and body.
At the molecular level, syntaxin serves as a switch and changes shape from a "closed" to an "open" state. Once in the "open" state, syntaxin acts in concert with other proteins to enable the release of the neurotransmitters.
When syntaxin or other proteins involved in this process are defective, certain neurological disorders can arise.
"Using an experimental model, we introduced a version of syntaxin that was locked in the 'open' state," Dr. Sugita says. "This version of syntaxin was able to overcome losses in proteins that are implicated in a wide spectrum of childhood epilepsy and autism spectrum disorders."
These findings position syntaxin as a key player in synaptic transmission, and suggest that drugs, and other small molecules, could be developed to push syntaxin to the "open" state as part of a strategy to treat certain neurological diseases.
This work was supported by the Natural Sciences and Engineering Research Council of Canada, the Canadian Institutes of Health Research, The Welch Foundation, National Natural Science Foundation of China, the United States National Institute of Neurological Disorders and Stroke, the Dengfeng Initiative of the Global Talents Recruitment Program, and the Toronto General & Western Hospital Foundation.